• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高级别浆液性卵巢癌新辅助化疗期间肿瘤免疫微环境的动态变化

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer.

作者信息

Lee Yong Jae, Woo Ha Young, Kim Yoo-Na, Park Junsik, Nam Eun Ji, Kim Sang Wun, Kim Sunghoon, Kim Young Tae, Park Eunhyang, Joung Je-Gun, Lee Jung-Yun

机构信息

Department of Obstetrics and Gynecology, Institute of Women's Medical Life Science, Yonsei University College of Medicine, Seoul 03722, Korea.

Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul 02447, Korea.

出版信息

Cancers (Basel). 2022 May 6;14(9):2308. doi: 10.3390/cancers14092308.

DOI:10.3390/cancers14092308
PMID:35565437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9104540/
Abstract

The dynamic changes in the tumor immune microenvironment (TIME) triggered by neoadjuvant chemotherapy (NAC) have not been clearly defined in advanced-stage ovarian cancer. We analyzed the immunologic changes induced by NAC to correlate them with clinical outcomes. We compared the changes in the immune infiltration of high-grade serous carcinoma biopsies before and after NAC via immunohistochemistry (147 paired samples) and whole transcriptome sequencing (35 paired samples). Immunohistochemistry showed significantly increased PD-L1 levels and TIL levels after NAC. Whole transcriptome sequencing revealed that the stromal score, immune score, and cytolytic activity score significantly increased after NAC. An increased tumor-infiltrating lymphocyte (TIL) level in response to NAC was associated with shorter progression-free survival compared with decreased TIL level after NAC. In tumors with increased TIL levels after NAC, the relative fraction of CD8 T cells and regulatory T cells significantly increased with immunohistochemistry. Post-NAC tumors were enriched in gene sets associated with immune signaling pathways, such as regulatory T cell and JAK/STAT signaling pathways. NAC induced dynamic changes in the TIME that increased TIL levels, but their high abundance did not impart any survival benefit. Our data may provide therapeutic strategies to improve the survival benefit from immunotherapies in ovarian cancer.

摘要

新辅助化疗(NAC)引发的肿瘤免疫微环境(TIME)的动态变化在晚期卵巢癌中尚未明确界定。我们分析了NAC诱导的免疫变化,并将其与临床结果相关联。我们通过免疫组织化学(147对样本)和全转录组测序(35对样本)比较了NAC前后高级别浆液性癌活检组织中免疫浸润的变化。免疫组织化学显示NAC后PD-L1水平和肿瘤浸润淋巴细胞(TIL)水平显著升高。全转录组测序显示NAC后基质评分、免疫评分和细胞溶解活性评分显著增加。与NAC后TIL水平降低相比,NAC后TIL水平升高与无进展生存期缩短相关。在NAC后TIL水平升高的肿瘤中,免疫组织化学显示CD8 T细胞和调节性T细胞的相对比例显著增加。NAC后的肿瘤富含与免疫信号通路相关的基因集,如调节性T细胞和JAK/STAT信号通路。NAC诱导了TIME的动态变化,增加了TIL水平,但其高丰度并未带来任何生存益处。我们的数据可能为改善卵巢癌免疫治疗的生存益处提供治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/72ebadf1bcfd/cancers-14-02308-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/175130f3d235/cancers-14-02308-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/03e6c9533ba0/cancers-14-02308-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/4f5601441864/cancers-14-02308-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/72ebadf1bcfd/cancers-14-02308-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/175130f3d235/cancers-14-02308-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/03e6c9533ba0/cancers-14-02308-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/4f5601441864/cancers-14-02308-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e855/9104540/72ebadf1bcfd/cancers-14-02308-g004.jpg

相似文献

1
Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer.高级别浆液性卵巢癌新辅助化疗期间肿瘤免疫微环境的动态变化
Cancers (Basel). 2022 May 6;14(9):2308. doi: 10.3390/cancers14092308.
2
Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.新辅助化疗后晚期高级别浆液性卵巢癌残余肿瘤中程序性细胞死亡配体 1 和免疫检查点标志物的表达。
Gynecol Oncol. 2018 Dec;151(3):414-421. doi: 10.1016/j.ygyno.2018.08.023. Epub 2018 Oct 9.
3
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.卵巢癌的新辅助化疗导致三种肿瘤浸润淋巴细胞反应模式,这对免疫治疗有不同的影响。
Clin Cancer Res. 2017 Feb 15;23(4):925-934. doi: 10.1158/1078-0432.CCR-16-1433. Epub 2016 Sep 6.
4
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.新辅助化疗后基质淋巴细胞浸润与 HER2 阳性乳腺癌侵袭性残留疾病和无病生存率降低相关。
Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.
5
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.局部晚期三阴性乳腺癌中肿瘤浸润淋巴细胞、程序性死亡配体-1 表达与中性粒细胞-淋巴细胞比值的预后作用及临床相关性。
Cancer Res Treat. 2019 Apr;51(2):649-663. doi: 10.4143/crt.2018.270. Epub 2018 Jul 31.
6
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.新辅助化疗治疗的乳腺癌患者治疗前后分子亚型与基质免疫浸润的相互作用。
Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12.
7
Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.PD-L1 和 CD8+ T 淋巴细胞在输卵管卵巢高级别浆液性癌中的免疫分型预测无病生存期。
APMIS. 2021 May;129(5):254-264. doi: 10.1111/apm.13116. Epub 2021 Feb 25.
8
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.PD-L1 表达和 CD8+ 肿瘤浸润淋巴细胞在不同类型的输卵管卵巢癌中的表达及其在高级别浆液性癌中的预后价值。
Am J Surg Pathol. 2020 Aug;44(8):1050-1060. doi: 10.1097/PAS.0000000000001503.
9
[Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].[肿瘤浸润淋巴细胞在高级别浆液性卵巢癌中的临床意义]
Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):610-614. doi: 10.3760/cma.j.issn.0529-5807.2019.08.005.
10
Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.高级别浆液性卵巢癌中全切片成像和数字分析的免疫反应性特征
Tumour Biol. 2020 Nov;42(11):1010428320971404. doi: 10.1177/1010428320971404.

引用本文的文献

1
Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.乳腺癌和女性生殖道癌中的肿瘤浸润淋巴细胞:被忽视的潜力与未被探索的前沿领域。
Cancer Med. 2025 Jul;14(13):e71023. doi: 10.1002/cam4.71023.
2
Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma.新辅助化疗后,卵巢高级别浆液性癌患者的组蛋白去乙酰化酶6和程序性死亡配体-1表达上调。
Sci Rep. 2025 Jun 2;15(1):19231. doi: 10.1038/s41598-025-02329-9.
3
Impact of clinical trial participation on the survival of patients with newly diagnosed advanced ovarian cancer.

本文引用的文献

1
The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry.1999 - 2017年韩国宫颈癌、卵巢癌和子宫内膜癌的发病率及生存率:韩国中央癌症登记处
Obstet Gynecol Sci. 2021 Sep;64(5):444-453. doi: 10.5468/ogs.21116. Epub 2021 Aug 17.
2
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.阿维鲁单抗联合或不联合化疗序贯阿维鲁单抗维持治疗与单纯化疗用于未经治疗的上皮性卵巢癌患者(JAVELIN Ovarian 100):一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Sep;22(9):1275-1289. doi: 10.1016/S1470-2045(21)00342-9. Epub 2021 Aug 4.
3
临床试验参与对新诊断的晚期卵巢癌患者生存的影响。
Front Oncol. 2025 May 6;15:1591000. doi: 10.3389/fonc.2025.1591000. eCollection 2025.
4
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.新辅助派姆单抗治疗IV期高级别浆液性卵巢癌:II期新派姆单抗试验
Nat Commun. 2025 Apr 14;16(1):3520. doi: 10.1038/s41467-025-58440-y.
5
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.审视高级别浆液性卵巢癌中免疫检查点疗法的证据。
Heliyon. 2024 Oct 5;10(20):e38888. doi: 10.1016/j.heliyon.2024.e38888. eCollection 2024 Oct 30.
6
Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.激活素水平与卵巢上皮性癌中的淋巴细胞浸润相关。
Cancer Med. 2024 Sep;13(17):e7368. doi: 10.1002/cam4.7368.
7
Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomas.图像分析揭示了高级别浆液性卵巢癌中免疫格局、胶原蛋白结构与新辅助化疗之间的关联。
Heliyon. 2024 Jun 25;10(13):e33618. doi: 10.1016/j.heliyon.2024.e33618. eCollection 2024 Jul 15.
8
The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature.新辅助化疗对卵巢癌肿瘤微环境的影响:文献系统评价。
Int J Mol Sci. 2024 Jun 27;25(13):7070. doi: 10.3390/ijms25137070.
9
Single-cell RNA sequencing reveals the immune microenvironment landscape of osteosarcoma before and after chemotherapy.单细胞RNA测序揭示了骨肉瘤化疗前后的免疫微环境格局。
Heliyon. 2023 Dec 11;10(1):e23601. doi: 10.1016/j.heliyon.2023.e23601. eCollection 2024 Jan 15.
10
Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer.复发性卵巢癌行二次肿瘤细胞减灭术联合或不联合腹腔热灌注化疗
Gland Surg. 2023 Dec 26;12(12):1696-1704. doi: 10.21037/gs-23-293. Epub 2023 Dec 22.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).阿替利珠单抗、贝伐珠单抗联合化疗治疗新诊断的 III 期或 IV 期卵巢癌:安慰剂对照随机 III 期试验(IMagyn050/GOG 3015/ENGOT-OV39)。
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
4
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.化疗在乳腺癌中诱导动态免疫反应,影响治疗效果。
Nat Commun. 2020 Dec 2;11(1):6175. doi: 10.1038/s41467-020-19933-0.
5
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.新辅助化疗改变了晚期卵巢癌中效应细胞与抑制性免疫细胞的平衡。
Cancer Immunol Immunother. 2021 Feb;70(2):519-531. doi: 10.1007/s00262-020-02670-0. Epub 2020 Aug 27.
6
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy.对接受新辅助化疗的晚期卵巢癌患者进行间歇性肿瘤细胞减灭术时根治性手术的再思考
J Clin Med. 2020 Apr 24;9(4):1235. doi: 10.3390/jcm9041235.
7
Revising the WHO classification: female genital tract tumours.修订世卫组织分类:女性生殖器官肿瘤。
Histopathology. 2020 Jan;76(1):151-156. doi: 10.1111/his.13977.
8
Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.新辅助化疗后晚期高级别浆液性卵巢癌残留病灶的基因组分析。
Int J Cancer. 2020 Apr 1;146(7):1851-1861. doi: 10.1002/ijc.32729. Epub 2019 Nov 23.
9
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.一项新辅助化疗联合度伐利尤单抗和替西木单抗治疗晚期卵巢癌的 II 期研究:韩国妇科肿瘤学组研究(KGOG 3046),TRU-D。
J Gynecol Oncol. 2019 Nov;30(6):e112. doi: 10.3802/jgo.2019.30.e112.
10
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.细胞毒化疗作为一种免疫刺激剂:从分子角度看待癌症的免疫升温。
Front Immunol. 2019 Jul 17;10:1654. doi: 10.3389/fimmu.2019.01654. eCollection 2019.